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Summary
In the randomized, placebo-controlled, phase 3 MONALESSA-2 trial, in patients with hormone receptor positive 
(HR+) [the estrogen receptor (ER) and/or progesterone receptor (PR)] and human epidermal growth factor 2 receptor nega-
tive (HER2-) advanced breast cancer (BC), progression-free survival (PFS) was signifi cantly longer among those receiving 
ribociclib [cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor] plus letrozole compared to patients receiving placebo plus 
letrozole. Additionally, ER+/PR+ cohort demonstrated higher hazard ratio for PFS than ER+/PR- cohort (0.62 vs. 0.36). Evi-
dence from cell-line models suggests that PR signaling is tightly linked to cell-cycle regulation in terms of inhibition of CDK 
4/6 activity when exposed to progestin. A possible explanation of this fi nding may be that high PR expression could interfere 
with ribociclib activity on the cyclin-kinase level. Furthermore, it is questionable whether PR level determines the effi  cacy 
of ribociclib administration with higher levels of this receptor being predictive of ribociclib ineffi  cacy. Considering the 
safety profi le of ribociclib, it’s necessary to perform analysis of PFS among ER+/PR+ patients receiving ribociclib, to poten-
tially assess the cut-off  value of PR expression (or ER/PR ratio) as a predictive marker of CDK4/6 effi  cacy. 
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EKSPRESIJA HORMONSKIH RECEPTORA I AKTIVNOST RIBOCIKLIBA U KARCINOMOMU 
DOJKE S POZITIVNIM HORMONSKIM RECEPTORIMA I NEGATIVNIM RECEPTOROM 
ZA HUMANI EPIDERMALNI FAKTOR RASTA 2
Sažetak
MONALESSA-2 je placebo kontrolirana randomizirana klinička studija faze 3 koja je uključila bolesnike s uznapredo-
valim karcinomom dojke s pozitivnim hormonskim receptorima (HR+) [estrogenski receptori (ER) i/ili progesteronski re-
ceptori (PR)] te negativnim receptorom za humani epidermalni faktor rasta 2 (eng. HER2-). Studija je pokazala kako je 
preživljenje bez progresije bolesti (eng. PFS) bilo značajno dulje u onih bolesnika koji su primali ribociklib [inhibitor ciklin-
ovisne kinaze 4 i 6 (CDK4/6)] uz letrozol u usporedbi s pacijentima koji su primali placebo i letrozol. Međutim,  ER+/PR+ 
grupa imala je viši omjer rizika (eng. hazard ratio) za preživljenje bez progresije bolesti (PFS) od ER+/PR- grupe (0.62 vs. 
0.36). Dokazi iz modela staničnih linija sugeriraju kako je signalni put PR usko vezan za regulaciju staničnog ciklusa kod 
inhibicije aktivnosti CDK 4/6 nakon izlaganja progestinu. Moguće objašnjenje ovih saznanja može biti povezano s visokom 
ekspresijom PR koja interferira s aktivnošću ribocikliba na razine ciklin-kinaze.  Stoga, upitno je da li razina ekspresije PR 
receptora utječe na učinkovitost primjene ribocikliba, tj. da li njegova veća ekspresija može uzrokovati smanjenje učinkovi-
tosti ribocikliba. S obzirom na sigurnosni profi l ribocikliba, potrebno je izvršiti analize PFS vrijednosti bolesnika koji prima-
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ju ribociklib ovisno o razinama ekspresije hormonskih receptora  kako bi se potencijalno odredile vrijednosti ekspresije PR 
(ili ER/PR omjera) kao markera učinkovitosti inhibitora CDK4/6.
KLJUČNE RIJEČI: ribociklib, karcinom dojke, ekspresija hormonskih receptora
INTRODUCTION
Approximately 72% of all breast cancers (BC) 
are hormone receptor positive (HR+) [the estrogen 
receptor (ER) and/or progesterone receptor (PR)] 
and human epidermal growth factor receptor 2 
negative (HER2-) (1). Single HR+/HER2- (ER+/PR-/
HER2- or ER-/PR+/HER2-) BC has poorer progno-
sis than double HR+/HER2- (ER+/PR+/HER2-) BC. 
There is also diff erence in prognosis between single 
HR+/HER2- BCs. It is proven that ER-/PR+/HER2- 
has poorer disease free survival (DFS) and overall 
survival (OS) compared to  ER+/PR-/HER2- BC (2). 
Thus we can conclude that both estrogen and pro-
gesterone have an eff ect on HR+ BC cells. Endo-
crine therapy is the backbone of HR+/HER2- BC 
treatment. In early BC the endocrine therapy is con-
sidered curative, while in advanced BC its role is to 
control tumor growth and preserve quality of life. 
As in all advanced cancers, resistance to current 
therapy eventually develops, so there is constant 
need for alternative regiments that can overcome or 
at least delay resistance. One of these alternative 
regiments in advanced BC is combination of riboci-
clib [selective cyclin-dependent kinases 4 and 6 
(CDK4/6) inhibitor] and letrozole (aromatase in-
hibitor). Ribociclib plus letrozole was compared to 
placebo plus letrozole in Mammary Oncology As-
sessment of LEE011’s (Ribociclib’s) Effi  cacy and 
Safety (MONALEESA-2) randomized, placebo-
controlled, phase 3 trial (3). This combination was 
evaluated in postmenopausal woman with HR+/
HER2- recurrent or metastatic BC who had not re-
ceived any systemic therapy for advanced disease. 
Ribociclib plus letrozole was proven to be superior 
to letrozole alone in term of progression-free sur-
vival (PFS) [hazard ratio, 0.56; 95% confi dence in-
terval (CI), 0.43 to 0.72; P=3.29×10−6 for superiority] 
which was primary endpoint of the trial. 
Diff erent effi  cacy between the subgroups in the 
MONALESSA-2 trial
In the MONALESSA-2 trial, ribociclib was 
given orally 600 mg per day on a 3-weeks-on, 
1-week-off  schedule together with letrozole orally 
2.5 mg per day, until progression. Previous adju-
vant and neoadjuvant therapy with a nonsteroidal 
aromatase inhibitor was allowed only if disease-
free interval was more than 12 months. Looking at 
basic characteristics of included population, ER+ 
was present in almost all patients in the trial 
(99.4% in ribociclib and 99.7% in placebo group), 
while PR+ something less (81.1% in ribociclib and 
83.2% in placebo group) (Table 1). In the subgroup 
analysis diff erent patt ern of clinical effi  cacy oc-
curred. ER+/PR+ cohort demonstrated higher haz-
ard ratio for PFS than combined ER+/PR- and ER-/
PR+ cohort, 0.62 vs. 0.36, respectively (Table 2) (3). 
Since ER is positive in ~ 100% of patients, other 
subgroup included mostly ER+/PR-/HER2- while 
number of ER-/PR+/HER2- BCs is negligible. 
Therefore ribociclib could be more eff ective in the 
ER+/PR- than ER+/PR+ cohort. Possible explana-
tion for diff erent effi  cacy between the cohorts may 
be that high PR expression could interfere with 
ribociclib activity on cyclin-kinase level. 
PR expression and cyclin-kinase activity
Progestins cause inhibition of cellular prolif-
eration in T-47D BC cells, which is preceded by 
Table 1. 
CHARACTERISTICS OF THE PATIENTS AT BASELINE 
REGARDING HR EXPRESSION








(N = 334) 332 (99.4) 2 (0.6) 271 (81.1) 63 (18.9)
Placebo (N 
= 334) 333 (99.7) 1 (0.3) 278 (83.2) 56 (16.8)
* Hormone receptor-HR, Estrogen receptor-ER, Progesterone receptor-PR 
Table 2. 








0.62 (0.46–0.82) 0.36 (0.20–0.65)
* Hormone receptor-HR, Progression-free Survival-PFS, , Estrogen recep-
tor-ER, Progesterone receptor-PR, , Confi dence interval-CI
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decreased cyclin abundance and G1 cyclin-de-
pendent kinase (CDK) activities (4). G1 CKDs are 
cyclin D-CDK4/6 and cyclin E-CDK2, whose ac-
tivity is governed by changes in cyclin abun-
dance and interactions with CDK inhibitors. 
CKD inhibitors from INK4 family form complex-
es with CDK4 and CDK6. Swarbrick and col-
leagues demonstrated in vitro that progestin 
treatment causes higher expression of CDK4/6 
inhibitors, and inhibition of cellular proliferation 
in BC cells follows (4). Dysregulated cyclin D-
CDK4/6-INK4-retinoblastoma (Rb) pathway is 
frequently observed in cancer and could result in 
tumor progression (5). Cyclin D1, which is en-
coded by CCND1 gene, regulates ERα transacti-
vation (6) and since CDK4/6 overexpression and 
CCND1 amplifi cation is often seen in HR+ BC (7), 
CDK4/6 inhibitors became a therapeutic option 
for advanced HR+/HER2- disease. 
Letrozole use and progesterone level
Recently interesting fi nding was reported 
by Alviggi and associates regarding letrozole use 
and progesterone level in mid-luteal phase in 
three young BC patients undergoing controlled 
ovarian stimulation (COS) [8]. Very high proges-
terone values (mean 186.6 ± 43.6 ng/mL) were de-
tected in these small case series, which are prob-
ably related with the use of letrozole indepen-
dently of the most commonly used trigger 
regimen [human chorionic gonadotropin (hCG) 
or GnRH agonist (GnRH-a)]. Authors suggest 
that letrozole and consequently inhibition of the 
estrogen-negative feedback on hypothalamus-
pituitary axis can cause low estrogen level in lu-
teal phase (8). There is diff erence in the dosing of 
letrozole in COS and HR+ BC treatment (5 mg/
day and 2.5 mg/day) that can possibly contribute 
to somewhat higher progesterone level. Howev-
er, we do not consider that this double dose of 
letrozole in COS can contribute in that extent to 
such a huge diff erence in progesterone level. In 
other observational trial with 21 BC patients who 
underwent COS with letrozole, progesterone lev-
els did not diff er signifi cantly (P=0.092) in con-
trast to group of 21 infertile patients who under-
went COS [9]. However, almost half of the popu-
lation in the study group received GnRH 
antagonist, which could bias the results regard-
ing progesterone level (9). 
Population that can have the most benefi t from 
CDK4/6 inhibitor treatment
In the era of various new small molecules 
and monoclonal antibodies, subpopulation analy-
sis should be conducted to determine which sub-
population will have benefi t from this kind of 
treatment and which not. It is common that new 
antineoplastic drugs are quite toxic for patients, 
and also toxic fi nancially for health care insuranc-
es. When ribociclib was compared to placebo 
group, it has reported a higher incidence of any 
adverse event, especially those of Grade 3 and 
Grade 4 (3). Thus it is quite important, besides 
pharmacoeconomic analysis, to determine which 
patients are the most suitable for ribociclib admin-
istration. 
Connecting in vitro fi ndings with fi ndings 
from the clinical trials of ribociclib we can noticed 
several interesting fi ndings. Since letrozole caused 
higher progesterone levels in mid-luteal phase we 
can assume that this progesterone can bind to 
ER+/PR+/HER2- BC cells and cause higher expres-
sion of CDK4/6 inhibitors and consequently com-
pete with ribociclib activity. Since ribociclib dem-
onstrated more superior in ER+/PR- than ER+/PR+ 
cohort it would be necessary to perform analysis 
of PFS among ER+/PR+ cohort in order to poten-
tially assess the cut-off  value of PR expression (or 
ER/PR ratio) as a predictive marker of CDK4/6 in-
hibitor effi  cacy. Amplifi cation of CCND1 gene, 
which regulates ERα transactivation, is often seen 
in HR+ BC. Thus we can assume that CDK4/6 in-
hibitor would be effi  cient in BC cells that have ER+ 
expression, but not in those that have only PR+ ex-
pression. Looking at the results of the MONALES-
SA-2 trial we come out with a conclusion that ribo-
ciclib has not proven its effi  cacy in the ER-/PR+/
HER2- cohort. ER+ was present in 99.4% and 
99.7% of patients in ribociclib and placebo groups, 
thus in the ER-/PR+/HER2- cohort was only 2 pa-
tients in ribociclib and 1 in placebo group (3). 
Intrinsic luminal subtype is also strong prog-
nostic factor in BC. Luminal B BC has a poorer 
prognosis than Luminal A BC [10], In the MONA-
LESSA-2 trial there was no subpopulation analy-
sis regarding Luminal type BC, which could also 
possibly reveal the more rational use of the 
CDK4/6 inhibitors.
If we look for the incidence of HR+/HER2- BC 
subtypes among all BC population, it is 59%, 4.5%, 
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and 0.9% for ER+/PR+/HER2-, ER+/PR-/HER2-, 
and ER-/PR+/HER2-, respectively [2]. Therefore it 
is quite a large population that can be candidates 
for ribociclib therapy if they develop advanced 
disease.
CONCLUSION 
Due to safety and pharmacoeconomic con-
sideration, ribociclib plus letrozole should be giv-
en in the advanced HR+/HER2- BC: in the ER+/
PR- cohort and in ER+/PR+ cohort. However, the 
cut-off  value of PR expression (or ER/PR ratio) in 
the ER+/PR+ cohort should be conducted fi rst, to 
determine CDK4/6 inhibitor effi  cacy regarding PR 
expression. Currently, there is no evidence that ri-
bociclib plus letrozole should be used in ER-/PR+/
HER2- BC. 
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